ASH News Daily - Saturday, December 10, 2011 - (Page A-15)

Saturday, December 10, 2011 QUALITY The Importance of Quality Indicators — By aManda Brandow, do, MS What You Need to Know Now Center. In particular, presenters will discuss how quality indicator measures are derived, how they can be measured, the potential consequences of failure to adhere to these indicators, and the challenges that quality indicators pose to particular hematologic populations. Dr. Richard Lottenberg, Univer- A re established quality indicators of sufficient quality for individual populations? This afternoon, attendees will have the opportunity to learn about the importance of quality indicators at the ASH special symposium, “Quality Indicators: Examples of Relevance to Hematology” that will be held from 2:00 to 3:30 p.m. in Room 30 of the San Diego Convention sity of Florida, Gainesville, will discuss the challenges in defining the quality of health care for patients with sickle cell disease (SCD). Spe- ASH NEWS DAILY Page A–15 ® cifically, Dr. Lottenberg will discuss how the small number of randomized, controlled trials in SCD poses challenges for the development of quality indicators. In addition, he will present recent developments relevant to the establishment of quality indicators in SCD and the benefits of having well-defined quality indicators in SCD. Dr. Lottenberg will highlight how operationalizing quality indicators in SCD is a work in progress, since there are real chal- lenges to providing SCD care even when there is strong evidence for improved outcomes. Dr. Lottenberg will also discuss the need to be aware of unintended consequences when developing quality indicators for SCD. “There needs to be validation of outcome measures. We need to assure quality indicators serve to enhance the capabilities of providers, rather »» QUALITY Page A-18 Tweets from An innovative approach to improving outcomes in patients with cancer This could allow potent Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2 drugs to be delivered directly to tumor cells with minimal systemic toxicity. Optimizing the parameters for clinical success Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs, including target antigen selection,3,4 linker stability5-7 and potent cytotoxic agents.4,7,8 Elements of an antibody-drug conjugate Linker Antibody specific for a tumor-associated antigen that has restricted expression on normal cells4,8 Cytotoxic agent kills target cells when internalized and released4,8 attaches the cytotoxic agent to the antibody. Newer linker systems are designed to be systemically stable and release the cytotoxic agent in targeted cancer cells4,8,9 ADCs link precision and potency for greater activity A preclinical (in vivo) study demonstrated that the ADC is more active than the antibody alone (mAb) or the admixture (mAb + cytotoxic agent unlinked)10 #ASH11 Chewing on great career development advice at #ASH11 Simultaneously exciting and ulcer-inducing... – prknlot At Successes in Bone Marrow Failures Symposium. Good session at #ASH11 – marrow Excited to hear updates from my colleagues attending @ ASH_hematology annual meeting. #ASH11 – hayeslat Loving 68 degree weather and palm trees in San diego. #ASH11 – alantanmd Science editor en route to #ASH11. If the crew needs to ask “is there a doctor on the plane?” they will be all SET. – BioWorld Kind of geeking out that #ASH11 has its own iPhone app! – deepfriedlard The future of drug treatment in cancer Seattle Genetics is dedicated to improving the lives of people with cancer by developing innovative therapies for hematologic malignancies and solid tumors. Go to seattlegenetics.com for your complimentary, comprehensive, 15-slide educational presentation. Just click on the download icon to get the slides delivered to your personal computer or mobile device. Download ADC scientific slide deck > Just landed for #ASH11 and there is a guy in just boxers at the baggage claim... – derekwimmer Here in #ASH11 waiting T-cell lymphoma session. San Diego CA – humbertosinco Leadership in antibody-drug conjugate development www.seattlegenetics.com REFERENCES: 1. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010;21(1):5-13. 2. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-1146. 3. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11(4):659-687. 4. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14(3):154-169. 5. Alley SC, Benjamin DR, Jeffrey SC, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-765. 6. Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. 7. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529-537. 8. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235-244. 9. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non–Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6): 2358-2364. 10. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778-784. Seattle Genetics and © 2011 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved. are US registered trademarks of Seattle Genetics, Inc. Printed in USA US/ADC/2011/0030 Just got back from #ASH11 registration. Loved the monitor for the Twitter Feed. Are you following @ASH_hematology? Lisa_Palacios – Headed out to San Diego for #ASH11. – jghoggatt Join the annual meeting conversation on Twitter. Use #ASH11 in your tweets from the meeting. Follow ASH on Twitter (@ash_hematology) for Society news, meeting information, advocacy updates, and much more. 10/25/11 2:37 PM

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com